查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574770

診斷市場：按產品類型、應用和最終用戶分類 - 2025-2030 年全球預測

Diagnostic Substances Market by Product Type (Instruments, Kits & Assays, Reagents), Application (Clinical Diagnostics, Forensic, Research), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年診斷市值為2048.4億美元，預計到2024年將達到2156.3億美元，複合年成長率為6.02%，到2030年將達到3085.3億美元。

診斷市場包括用於疾病診斷的材料，例如試劑、校準品、控制材料、套件和相關設備。隨著慢性病和感染疾病的增加，診斷試劑用於臨床實驗室、醫院、即時檢測和研究機構，以進行徹底的評估、健康監測和有效的患者管理。最終用途產業涵蓋醫療保健、生物技術和製藥，推動了從常規測試到高階分子診斷的應用。關鍵的成長要素包括健康意識提高導致的需求增加、促進床邊生物感測器等創新產品的技術進步以及加速市場進入的有利法規環境。此外，疾病發生率的增加需要準確、快速的診斷，以改善醫療保健結果並降低成本。

主要市場統計
基準年[2023] 2048.4億美元
預測年份 [2024] 2156.3億美元
預測年份 [2030] 3085.3億美元
複合年成長率（%） 6.02%

在基因組學和蛋白​​質組學進步的推動下，個人化醫療的引入帶來了新的商機，從而推動了對專業診斷的需求。人工智慧和巨量資料分析在診斷中的使用為精準醫療和即時健康監測提供了巨大的市場潛力。然而，高昂的開發成本、嚴格的監管環境和資料隱私問題等挑戰可能會阻礙市場的進步。將新技術整合到現有系統中的複雜性進一步增加了營運障礙。鼓勵創新和研究開發具有更高靈敏度和特異性的照護現場診斷設備，針對資源有限的環境，解決發展中地區未滿足的需求。與實驗室晶片技術一起，生物標記的發現和檢驗提供了一條充滿希望​​的成長途徑。

儘管存在這些障礙，但鑑於醫療保健成本不斷上升以及醫療保健提供者和技術公司之間為簡化診斷程序而進行的合作，診斷市場仍有望擴大。為了成功駕馭不斷變化的市場格局，建議採用強調擴充性、永續性和以患者為中心的解決方案的適應性方法。此外，採用環保生產流程和數位健康創新可以確保產業參與者的永續競爭優勢。

市場動態：揭示快速發展的診斷市場的關鍵市場洞察

供需的動態交互作用正在改變診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 診斷技術的進步和慢性病盛行率的上升推動市場成長
    • 增加政府措施和資金以改善全球醫療保健基礎設施
    • 擴大照護現場診斷設備的採用，以改善患者照護和治療結果
    • 對疾病早期檢測和個人化醫療的需求不斷成長推動市場擴張
  • 市場限制因素
    • 不斷變化的醫療保健政策和報銷問題對診斷市場的成長產生負面影響
    • 低度開發地區先進診斷技術的取得和可用性有限阻礙了市場潛力
  • 市場機會
    • 癌症治療中個人化醫療的先進診斷生物標記
    • 用於在偏遠地區快速檢測感染疾病的照護現場診斷測試
    • 使用人工智慧進行預測診斷以早期發現神經退化性疾病
  • 市場挑戰
    • 缺乏熟悉診斷的熟練專業人員會影響市場成長和創新

波特五力：駕馭診斷市場的策略工具

波特的五力框架是了解診斷市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解診斷市場的外部影響

外部宏觀環境因素在塑造診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解診斷藥物市場的競爭狀況

診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣診斷市場供應商績效評估

FPNV定位矩陣是評估診斷市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議 規劃診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 診斷技術的進步和慢性病的增加推動市場成長
      • 政府加強並提供資金以改善世界各地的醫療基礎設施
      • 更多地採用照護現場診斷設備以改善患者護理和治療結果
      • 對疾病早期檢測和個人化醫療的需求不斷成長正在推動市場擴張
    • 抑制因素
      • 不斷變化的醫療保健政策和報銷問題將對診斷市場的成長產生負面影響
      • 發展中地區先進診斷技術的取得和可用性有限，限制了市場潛力。
    • 機會
      • 癌症治療中個人化醫療的先進診斷生物標記
      • 用於快速檢測偏遠地區感染疾病的照護現場診斷測試
      • 人工智慧驅動的預測診斷用於神經退化性疾病的早期檢測
    • 任務
      • 缺乏具有診斷專業知識的熟練專業人員會影響市場成長和創新。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章診斷市場：依產品類型

  • 裝置
    • 分析儀
    • 次世代定序
    • PCR機
  • 套件和檢測
    • 酵素連結免疫吸附測定試劑套件
    • 橫向流動化驗
    • PCR試劑套件
  • 試劑
    • 抗體
    • 胜肽
    • 蛋白質

第7章診斷市場：依應用分類

  • 臨床診斷
    • 心臟病學
    • 感染疾病
    • 腫瘤學
  • 法醫學
    • 病理
    • 毒理學
  • 研究
    • 藥物發現
    • 基因組學
    • 蛋白質體學

第 8 章診斷市場：依最終使用者分類

  • 診斷實驗室
    • 醫院實驗室
    • 獨立實驗室
  • 醫院/診所
    • 私立醫院
    • 公立醫院
  • 製藥公司
    • 臨床試驗
    • 藥物開發
  • 調查機構
    • 學術研究
    • 政府調查

第9章 北美、南美診斷試劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Cepheid
  • 7. Danaher Corporation
  • 8. DiaSorin SpA
  • 9. Genomic Health Inc.
  • 10. Hoffmann-La Roche AG
  • 11. Hologic Inc.
  • 12. Illumina Inc.
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. PerkinElmer Inc.
  • 16. Qiagen NV
  • 17. Quidel Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation
  • 20. Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C040C

The Diagnostic Substances Market was valued at USD 204.84 billion in 2023, expected to reach USD 215.63 billion in 2024, and is projected to grow at a CAGR of 6.02%, to USD 308.53 billion by 2030.

The diagnostic substances market encompasses materials used for diagnosing diseases, encompassing reagents, calibrators, control materials, kits, and related instruments. Necessitated by the increasing prevalence of chronic and infectious diseases, diagnostic substances are applied in clinical laboratories, hospitals, point-of-care testing, and research institutions for conducting meticulous assessments, monitoring health conditions, and ensuring effective patient management. End-use industries span healthcare, biotechnology, and pharmaceuticals, driving diverse applications from routine tests to advanced molecular diagnostics. Key growth influencers include escalating demand due to rising health awareness, technological advancements fostering innovative products like point-of-care biosensors, and supportive regulatory environments accelerating market entry. Additionally, the growing incidence of diseases necessitates accurate, swift diagnosis to improve healthcare outcomes and reduce costs.

KEY MARKET STATISTICS
Base Year [2023] USD 204.84 billion
Estimated Year [2024] USD 215.63 billion
Forecast Year [2030] USD 308.53 billion
CAGR (%) 6.02%

Emerging opportunities are notably visible in the adoption of personalized medicine, fueled by genomic and proteomic advancements, propelling demand for specialized diagnostic substances. Leveraging artificial intelligence and big data analytics in diagnostics offers substantial market potential for precision medicine and real-time health monitoring. However, challenges such as high development costs, stringent regulatory landscapes, and data privacy issues can impede market progression. Complexities in integrating new technologies within existing systems further pose operational hurdles. Encouragement of innovation and research is directed towards developing point-of-care diagnostic devices with enhanced sensitivity and specificity, targeting resource-constrained settings to cater to unmet needs in developing regions. Exploring biomarker discovery and validation, alongside lab-on-a-chip technologies, presents promising avenues for growth.

Despite these hurdles, the diagnostic substances market is poised for expansion, given the increasing healthcare expenditures, alongside collaborations between healthcare providers and technological firms striving to streamline diagnostic procedures. An adaptable approach emphasizing scalability, sustainability, and patient-centric solutions is recommended to navigate the evolving market landscape successfully. Subsequently, embracing eco-friendly production processes and digital health innovations ensures sustained competitive advantage for industry participants.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diagnostic Substances Market

The Diagnostic Substances Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Advancements in diagnostic technologies and rising prevalence of chronic diseases boosting market growth
    • Increasing government initiatives and funding to improve healthcare infrastructure worldwide
    • Growing adoption of point-of-care diagnostic devices to enhance patient care and outcomes
    • Rising demand for early disease detection and personalized medicine driving market expansion
  • Market Restraints
    • Evolving healthcare policies and reimbursement issues negatively impact diagnostic substances market growth
    • Limited accessibility and availability of advanced diagnostic technologies in underdeveloped regions hinder market potential
  • Market Opportunities
    • Advanced diagnostic biomarkers for personalized medicine in cancer treatment
    • Point-of-care diagnostic tests for rapid infectious disease detection in remote areas
    • AI-driven predictive diagnostics for early detection of neurodegenerative diseases
  • Market Challenges
    • Limited availability of skilled professionals with expertise in diagnostic substances impacts market growth and innovation

Porter's Five Forces: A Strategic Tool for Navigating the Diagnostic Substances Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diagnostic Substances Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diagnostic Substances Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diagnostic Substances Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diagnostic Substances Market

A detailed market share analysis in the Diagnostic Substances Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diagnostic Substances Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diagnostic Substances Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diagnostic Substances Market

A strategic analysis of the Diagnostic Substances Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diagnostic Substances Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, Cepheid, Danaher Corporation, DiaSorin S.p.A., Genomic Health Inc., Hoffmann-La Roche AG, Hologic Inc., Illumina Inc., Merck KGaA, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen N.V., Quidel Corporation, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Diagnostic Substances Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments, Kits & Assays, and Reagents. The Instruments is further studied across Analyzers, Next-Generation Sequencing, and PCR Machines. The Kits & Assays is further studied across Elisa Kits, Lateral Flow Assays, and PCR Kits. The Reagents is further studied across Antibodies, Peptides, and Proteins.
  • Based on Application, market is studied across Clinical Diagnostics, Forensic, and Research. The Clinical Diagnostics is further studied across Cardiology, Infectious Diseases, and Oncology. The Forensic is further studied across Pathology and Toxicology. The Research is further studied across Drug Discovery, Genomics, and Proteomics.
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, Pharmaceutical Companies, and Research Institutes. The Diagnostic Laboratories is further studied across Hospital-Based Labs and Independent Labs. The Hospitals & Clinics is further studied across Private Hospitals and Public Hospitals. The Pharmaceutical Companies is further studied across Clinical Trials and Drug Development. The Research Institutes is further studied across Academic Research and Government Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Advancements in diagnostic technologies and rising prevalence of chronic diseases boosting market growth
      • 5.1.1.2. Increasing government initiatives and funding to improve healthcare infrastructure worldwide
      • 5.1.1.3. Growing adoption of point-of-care diagnostic devices to enhance patient care and outcomes
      • 5.1.1.4. Rising demand for early disease detection and personalized medicine driving market expansion
    • 5.1.2. Restraints
      • 5.1.2.1. Evolving healthcare policies and reimbursement issues negatively impact diagnostic substances market growth
      • 5.1.2.2. Limited accessibility and availability of advanced diagnostic technologies in underdeveloped regions hinder market potential
    • 5.1.3. Opportunities
      • 5.1.3.1. Advanced diagnostic biomarkers for personalized medicine in cancer treatment
      • 5.1.3.2. Point-of-care diagnostic tests for rapid infectious disease detection in remote areas
      • 5.1.3.3. AI-driven predictive diagnostics for early detection of neurodegenerative diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled professionals with expertise in diagnostic substances impacts market growth and innovation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diagnostic Substances Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
    • 6.2.1. Analyzers
    • 6.2.2. Next-Generation Sequencing
    • 6.2.3. PCR Machines
  • 6.3. Kits & Assays
    • 6.3.1. Elisa Kits
    • 6.3.2. Lateral Flow Assays
    • 6.3.3. PCR Kits
  • 6.4. Reagents
    • 6.4.1. Antibodies
    • 6.4.2. Peptides
    • 6.4.3. Proteins

7. Diagnostic Substances Market, by Application

  • 7.1. Introduction
  • 7.2. Clinical Diagnostics
    • 7.2.1. Cardiology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Oncology
  • 7.3. Forensic
    • 7.3.1. Pathology
    • 7.3.2. Toxicology
  • 7.4. Research
    • 7.4.1. Drug Discovery
    • 7.4.2. Genomics
    • 7.4.3. Proteomics

8. Diagnostic Substances Market, by End User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
    • 8.2.1. Hospital-Based Labs
    • 8.2.2. Independent Labs
  • 8.3. Hospitals & Clinics
    • 8.3.1. Private Hospitals
    • 8.3.2. Public Hospitals
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Clinical Trials
    • 8.4.2. Drug Development
  • 8.5. Research Institutes
    • 8.5.1. Academic Research
    • 8.5.2. Government Research

9. Americas Diagnostic Substances Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Diagnostic Substances Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Diagnostic Substances Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories Inc.
  • 5. bioMerieux SA
  • 6. Cepheid
  • 7. Danaher Corporation
  • 8. DiaSorin S.p.A.
  • 9. Genomic Health Inc.
  • 10. Hoffmann-La Roche AG
  • 11. Hologic Inc.
  • 12. Illumina Inc.
  • 13. Merck KGaA
  • 14. Ortho Clinical Diagnostics
  • 15. PerkinElmer Inc.
  • 16. Qiagen N.V.
  • 17. Quidel Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. DIAGNOSTIC SUBSTANCES MARKET RESEARCH PROCESS
  • FIGURE 2. DIAGNOSTIC SUBSTANCES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIAGNOSTIC SUBSTANCES MARKET DYNAMICS
  • TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITAL-BASED LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GOVERNMENT RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 240. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 266. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 279. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 292. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 303. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 304. VIETNAM DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 319. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
  • TABLE 329. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
  • TABLE 330. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 331. DENMARK DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 332.